Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year

CNBC

Eli Lilly is racing to market donanemab for Alzheimer’s after Eisai and Biogen’s drug for the disease, Leqembi, won FDA approval this month.